---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-000947"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:32:49.879594+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics cuts workforce 30%, narrows focus on two clinical programs, reports $330M cash runway into 2027

## Summary
- Workforce reduction of ~30% (45 positions) substantially complete by end of Q1 2024; estimated charges of ~$3M.
- Unaudited cash, equivalents, and marketable securities of ~$330M as of Jan 5, 2024; expects cash runway into 2027.
- Raised ~$107M: $25M Betta equity, $10M Merck upfront, $72M net from ATM (13.7M shares at avg $5.42).
- Prioritizes CFT7455 (multiple myeloma/NHL) and CFT1946 (solid tumors) Phase 1/2 trials; data in 2H 2024.
- Supports CFT8919 partner trial (Betta) and collaborations with Roche, Biogen, Merck; internal discovery streamlined.

## SEC filing metadata
- accession: 0001628280-24-000947
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/0001628280-24-000947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/cccc-20240109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-000947
- JSON: https://secwatch.observer/filing/0001628280-24-000947.json
- Plain text: https://secwatch.observer/filing/0001628280-24-000947.txt

## Key facts
- Restructurings & Charges
  C4 Therapeutics, Inc. announced a restructuring with charges of approximately $3 million (approximately 30% of the workforce or 45 positions).
  - Type: restructuring
  - Charge: approximately $3 million
  - Headcount: approximately 30% of the workforce or 45 positions
  source text: The employees impacted by the strategic imperatives and resulting Restructuring were notified on January 9, 2024 and represent approximately 30% of the workforce or 45 positions. The reductions will be substantially complete by the end of the first quarter of 2024. As a result of these changes, the Company estimates that it will incur charges of approximately $3 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024000947/0001628280-24-000947-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.